Monocyte Profiles in Critically Ill Patients With Pseudomonas Aeruginosa Sepsis

ConditionsPseudomonas Infections Pseudomonas Septicemia Pseudomonas; Pneumonia Pseudomonal Bacteraemia Pseudomonas Urinary Tract Infection Pseudomonas Gastrointestinal Tract Infection Sepsis Sepsis, Severe Critically Ill

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18-90

SponsorUniversity of Ulm

About this trial

The present study focuses on patients with Pseudomonas aeruginosa (PSA) sepsis. The aim of the present study is to find out whether the M1 (pro-inflammatory) or M2 (anti-inflammatory) phenotype predominates in blood monocytes in critically ill patients with PSA-sepsis, and whether the severity of sepsis and outcome is associated with distinct monocyte phenotype and function.

Eligibility criteria

Qualifiers

age > 18 years

critically ill patients with sepsis

microbiologically proven infection with Pseudomonas aeruginosa

Disqualifiers

life expectancy < 24 hours

participation in other studies

Trial design

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Locations

Clinic of Anesthesiology89070, Ulm Germany

Sponsors and collaborators

University of Ulm

Lead sponsor

Source ClinicalTrials.gov